ALMS vs LLY
ALMS: A clinical-stage biopharmaceutical company developing TYK2 inhibitors to replace broad immunosuppression with targeted therapies for immune-mediated diseases, with lead candidate envu advancing toward 2026 FDA submission. LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth.
Side-by-side fundamentals
| Metric | ALMS | LLY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.81 | $1,163.01 | |
| Market cap as of 2026-07-23 | $3.8B | $1.09T | |
| P/E as of 2026-07-23 | n/a | 43.27 | |
| PEG as of 2026-07-23 | n/a | 1.37 | |
| Net margin as of 2026-07-23 | -1013.2% | +35.0% | LLY higher |
| Gross margin as of 2026-07-23 | n/a | +82.8% | |
| Operating margin as of 2026-07-23 | -1109.1% | +43.6% | LLY higher |
| ROE as of 2026-07-23 | -54.7% | +101.3% | LLY higher |
| ROA as of 2026-07-23 | -43.6% | +22.7% | LLY higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.39 | ALMS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +47.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +31.7% | |
| Dividend yield as of 2026-07-23 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.82 | 0.51 | |
| 1-year return as of 2026-07-22 close | +805.1% | +49.8% | ALMS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.